David Chiswell, Ph.D.

Chairman of the Board, Albireo; Chief Executive Officer, Kymab

After a career as a research scientist in both the United Kingdom and the United States and nine years working in scientific management at Amersham International, David Chiswell co-founded Cambridge Antibody Technology (CAT) and served as its CEO for several years. In addition to Albireo, Dr. Chiswell is currently CEO of Kymab Ltd.  

He was previously chairman of the UK’s BioIndustry Association (BIA) and remains on its board. In 2006, Dr. Chiswell was awarded the OBE by HM Queen for services to the biotechnology industry.

Team members

David Chiswell, Ph.D.

Chairman of the Board, Albireo; Chief Executive Officer, Kymab

Julia R. Brown

Former Executive Vice President and Advisor to the CEO, Amylin Pharmaceuticals (retired)

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics (retired)

Heather Preston, M.D.

Partner & Managing Director, TPG Biotech

Davey S. Scoon

Chair of the Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer